A mutation in helicase motif IV of herpes simplex virus type 1 UL5 that results in reduced growth in vitro and lower virulence in a murine infection model is related to the predicted helicase structure

被引:24
作者
Biswas, Subhajit [1 ]
Miguel, Ricardo Nunez [2 ]
Sukla, Soumi [1 ]
Field, Hugh J. [1 ]
机构
[1] Univ Cambridge, Dept Vet Med, Cambridge, England
[2] Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England
关键词
PRIMASE INHIBITOR BAY-57-1293; CONFER RESISTANCE; PROTEIN; HSV-1; DEFICIENT;
D O I
10.1099/vir.0.011221-0
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
A variant was selected from a clinical isolate of herpes simplex virus type 1 (HSV-1) during a single passage in the presence of a helicase-primase inhibitor (HPI) at eight times the IC50. The variant was approximately 40-fold resistant to the HPI BAY 57-1293 and it showed significantly reduced growth in tissue culture with a concomitant reduction in virulence in a murine infection model. The variant contained a single mutation (Asn342Lys) in the UL5 predicted functional helicase motif IV. The Asn342Lys mutation was transferred to a laboratory strain, PDK cl-1, and the recombinant acquired the expected resistance and reduced growth characteristics. Comparative modelling and docking studies predicted the Asn342 position to be physically distant from the HPI interaction pocket formed by UL5 and UL52 (primase). We suggest that this mutation results in steric/allosteric modification of the HPI-binding pocket, conferring an indirect resistance to the HPI. Slower growth and moderately reduced virulence suggest that this mutation might also interfere with the helicase-primase activity.
引用
收藏
页码:1937 / 1942
页数:6
相关论文
共 26 条
[1]   Single amino acid substitutions in the HSV-1 helicase protein that confer resistance to the helicase-primase inhibitor BAY 57-1293 are associated with increased or decreased virus growth characteristics in tissue culture [J].
Biswas, S. ;
Jennens, L. ;
Field, H. J. .
ARCHIVES OF VIROLOGY, 2007, 152 (08) :1489-1500
[2]   Mutations close to functional motif IV in HSV-1UL5 helicase that confer resistance to HSV helicase-primase inhibitors, variously affect virus growth rate and pathogenicity [J].
Biswas, Subhajit ;
Tiley, Laurence S. ;
Zimmermann, Holger ;
Birkmann, Alexander ;
Field, Hugh J. .
ANTIVIRAL RESEARCH, 2008, 80 (01) :81-85
[3]   A single drug-resistance mutation in HSV-1UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target [J].
Biswas, Subhajit ;
Kleymann, Gerald ;
Swift, Mihaiela ;
Tiley, Laurence S. ;
Lyall, Jonathan ;
Aguirre-Hernandez, Jesus ;
Field, Hugh J. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 61 (05) :1044-1047
[4]   Detection of HSV-1 variants highly resistant to the helicase-primase inhibitor BAY 57-1293 at high frequency 2 of 10 recent clinical isolates of HSV-1 [J].
Biswas, Subhajit ;
Smith, Christopher ;
Field, Hugh J. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 60 (02) :274-279
[5]  
Biswas Subhajit, 2008, Antiviral Chemistry & Chemotherapy, V19, P1
[6]   CHARMM - A PROGRAM FOR MACROMOLECULAR ENERGY, MINIMIZATION, AND DYNAMICS CALCULATIONS [J].
BROOKS, BR ;
BRUCCOLERI, RE ;
OLAFSON, BD ;
STATES, DJ ;
SWAMINATHAN, S ;
KARPLUS, M .
JOURNAL OF COMPUTATIONAL CHEMISTRY, 1983, 4 (02) :187-217
[7]   HOMSTRAD: adding sequence information to structure-based alignments of homologous protein families [J].
de Bakker, PIW ;
Bateman, A ;
Burke, DF ;
Miguel, RN ;
Mizuguchi, K ;
Shi, J ;
Shirai, H ;
Blundell, TL .
BIOINFORMATICS, 2001, 17 (08) :748-749
[8]   MUTANT STRAINS OF HERPES SIMPLEX DEFICIENT IN THYMIDINE KINASE-INDUCING ACTIVITY [J].
DUBBS, DR ;
KIT, S .
VIROLOGY, 1964, 22 (04) :493-&
[9]   PATHOGENICITY OF THYMIDINE KINASE-DEFICIENT MUTANTS OF HERPES-SIMPLEX VIRUS IN MICE [J].
FIELD, HJ ;
WILDY, P .
JOURNAL OF HYGIENE, 1978, 81 (02) :267-277
[10]   HELICASES - AMINO-ACID-SEQUENCE COMPARISONS AND STRUCTURE-FUNCTION-RELATIONSHIPS [J].
GORBALENYA, AE ;
KOONIN, EV .
CURRENT OPINION IN STRUCTURAL BIOLOGY, 1993, 3 (03) :419-429